Sonnet Biotherapeutics Holdings Inc (SONN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sonnet Biotherapeutics Holdings Inc (SONN) has a cash flow conversion efficiency ratio of 0.577x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.76 Million) by net assets ($-3.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SONN stock market capitalisation for the company's overall valuation and market capitalisation.
Sonnet Biotherapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Sonnet Biotherapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sonnet Biotherapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonnet Biotherapeutics Holdings Inc ranked by their cash flow conversion efficiency. Explore SONN operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STO Co. Ltd
KQ:098660
|
0.024x |
|
Gema Grahasarana Tbk
JK:GEMA
|
-0.034x |
|
Equity Development Investment
JK:GSMF
|
-0.023x |
|
Constellation Resources Ltd
AU:CR1
|
-1.081x |
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
-0.003x |
|
Silver Range Resources Ltd
V:SNG
|
-0.017x |
|
Renew Holdings plc
LSE:RNWH
|
0.122x |
|
Nuvotec
KQ:060260
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Sonnet Biotherapeutics Holdings Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Sonnet Biotherapeutics Holdings Inc from 2009 to 2025. View today's stock price for Sonnet Biotherapeutics Holdings Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $10.79 Million | $-12.83 Million | -1.189x | -106.71% |
| 2024-09-30 | $-485.74K | $-8.61 Million | 17.721x | -81.24% |
| 2023-09-30 | $-225.98K | $-21.34 Million | 94.441x | +765.96% |
| 2022-09-30 | $-2.54 Million | $-27.69 Million | 10.906x | +1176.46% |
| 2021-09-30 | $22.26 Million | $-22.55 Million | -1.013x | +80.41% |
| 2020-09-30 | $3.02 Million | $-15.61 Million | -5.171x | -761.04% |
| 2019-09-30 | $-2.85 Million | $-2.23 Million | 0.782x | +1340.48% |
| 2017-09-30 | $11.49 Million | $-724.43K | -0.063x | -72.91% |
| 2016-09-30 | $13.96 Million | $-509.16K | -0.036x | +85.21% |
| 2015-12-31 | $21.76 Million | $-5.36 Million | -0.247x | +31.18% |
| 2015-09-30 | $14.97 Million | $-5.36 Million | -0.358x | -48.88% |
| 2013-09-30 | $11.24 Million | $-2.70 Million | -0.241x | +62.19% |
| 2012-09-30 | $1.64 Million | $-1.04 Million | -0.636x | -6798.55% |
| 2011-09-30 | $82.42 Million | $-760.31K | -0.009x | +98.96% |
| 2009-09-30 | $718.02K | $-636.48K | -0.886x | -- |
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more